

Guidelines on the management of latent tuberculosis infection

THE
END TB
STRATEGY



World Health
Organization

WHO Library Cataloguing-in-Publication Data

Guidelines on the management of latent tuberculosis infection.

1.Latent Tuberculosis. 2.Immunologic Tests. 3.Mycobacterium Tuberculosis – immunology. 4.Antitubercular Agents.
5.Guideline. I.World Health Organization.

ISBN 978 92 4 154890 8 (NLM classification: WF 200)

© **World Health Organization 2015**

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design by North Creative, Geneva.

Printed in Spain.

WHO/HTM/TB/2015.01

Guidelines on the management of latent tuberculosis infection



Contents

Acknowledgements	2
Abbreviations	5
Declaration and management of conflict of interest	6
Executive summary	8
1. Background and process	10
1.1. Background	10
1.2. Scope of the guidelines	10
1.3. Target audience	10
1.4. Development of the guidelines	11
1.5. Quality of evidence and strength of the recommendations	12
2. Recommendations	13
2.1. Identification of at-risk populations for LTBI testing and treatment	13
2.2. Algorithm to test and treat LTBI	15
2.3. Treatment options for LTBI	18
2.4. Preventive treatment for contacts of MDR-TB cases	20
3. Issues in Implementation	22
3.1. Adverse events monitoring	22
3.2. Risk of drug resistance following LTBI treatment	22
3.3. Adherence and completion of preventive treatment	23
3.4. Ethical considerations	24
3.5. Cost effectiveness	24
3.6. Programme management, monitoring and evaluation	24
4. Research gaps	26
4.1. Risk of progression to active TB disease and differential impact by population risk group	26
4.2. Defining the best algorithm to test and treat LTBI	26
4.3. Treatment options for LTBI and adverse event monitoring	26
4.4. Risk of drug resistance following LTBI treatment	27
4.5. Adherence and completion of treatment	27
4.6. Cost-effectiveness studies	27
4.7. Preventive treatment for MDR-TB contacts	27
4.8. Programme management	27
5. References	28
6. Annexes	30
Annex 1: List of primary target countries for the guidelines	30
Annex 2: List of systematic reviews conducted	32
Annex 3: Recommended drug dosage	33
Annex 4: Evidence to decision framework (online only)	

Acknowledgements

Overall coordination and writing of the guidelines

Haileyesus Getahun and Alberto Matteelli helped coordinate the development and drafting of the guidelines, under the overall direction of Mario Raviglion.

WHO Steering Group

Dennis Falzon (Global TB Programme, WHO), Nathan Ford (HIV/AIDS Department, WHO), Haileyesus Getahun (Global TB Programme, WHO), Chris Gilpin (Global TB Programme, WHO), Christian Lienhardt (Global TB Programme, WHO), Knut Lonnroth (Global TB Programme, WHO), Alberto Matteelli (Global TB Programme, WHO), Lisa Nelson (HIV/AIDS Department, WHO), Andreas Reis (Knowledge, Ethics and Research Department, WHO), Mukund Uplekar (Global TB Programme, WHO).

Co-chairs of the WHO Guidelines Development Group

Holger Schünemann (McMaster University Health Sciences Centre, Canada); Jay Varma (US Centers for Diseases Control and Prevention, USA).

GRADE methodologist of the WHO Guidelines Development Group

Holger Schünemann (McMaster University Health Sciences Centre, Canada).

Members of WHO Guidelines Development Group

Ibrahim Abubakar (National Centre for Infectious Disease Surveillance and Control, University College London and Public Health England, London, United Kingdom of Great Britain and Northern Ireland); Draurio Barreira (National TB Programme, Ministry of Health, Brasilia, Brazil); Susana Marta Borroto Gutierrez (Pedro Kourí Institute of Tropical Medicine, La Habana, Cuba); Judith Bruchfeld (Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden); Erlina Burhan (Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia); Solange Cavalcante (Rio de Janeiro Municipal Health Secretariat FIOCRUZ, Rio de Janeiro, Brazil); Rolando Cedillos (Servicio de Infectología y Programade Atención Integral en ITS/VIH/SIDA, San Salvador, El Salvador); Cynthia Bin-Eng Chee (Tan Tock Seng Hospital, Singapore); Richard Chaisson (Center for TB Research, John Hopkins University, USA); Lucy Chesire (TB Advocacy Consortium, Nairobi, Kenya); Elizabeth Corbett (London School of Hygiene and Tropical Medicine, Blantyre, Malawi); Justin Denholm (Royal Melbourne Hospital, Melbourne, Australia); Gerard de Vries (KNCV TB Foundation, Den Haag, The Netherlands); Margaret Gale-Rowe (Public Health Agency of Canada, Ottawa, Canada); Un-Yeong Go (Department of HIV/AIDS and TB Control Korea, Korea Centers for Disease Control and Prevention, Republic of Korea); Alison Grant (London School of Hygiene and Tropical Medicine, London, United Kingdom of Great Britain and Northern Ireland); Robert Horsburgh (Department of Epidemiology, Boston University School of Public Health, Boston, USA); Asker Ismayilov (Main Medical Department, Ministry of Justice, Azerbaijan); Philippe LoBue (Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, USA); Guy Marks (Woolcock Institute of Medical Research University of Sydney, Sydney, Australia); Richard Menzies (Respiratory Division, McGill University, and Montreal Chest Institute, Montreal, Canada); Giovanni Battista Migliori (WHO Collaborating Centre for TB and Lung Diseases Fondazione S. Maugeri, Tradate, Italy); Davide Mosca (Migration Health Department, International Organization of Migration, Geneva, Switzerland); Ya Diul Mukadi (Infectious Disease Division, Bureau for Global Health, US Agency for International Development, Washington, USA); Alwyn Mwinga (Zambart Project, Lusaka, Zambia); Lisa Rotz (Centers for Disease Control and Prevention, Atlanta, USA); Holger Schünemann (Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Canada); Surender Kumar Sharma (Department of Medicine, All India Institute of Medical Sciences,

New Delhi, India); Timothy Sterling (Vanderbilt University School of Medicine, Nashville, USA); Tamara Tayeb (National TB Programme, Ministry of Health, Riyadh, Saudi Arabia); Marieke van der Werf (European Centre for Disease Prevention and Control, Stockholm, Sweden); Wim Vandeveld (European AIDS Treatment Group, Brussels, Belgium); Jay Varma (US Centers for Diseases Control and Prevention, USA); Natalia Vezhnina (Regional Advisor on HIV/TB and Penal System Projects, Russian Federation); Constantia Voniatis (Coordinator of Clinical Laboratories, Ministry of Health, Nicosia, Cyprus); Robert John Wilkinson (Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa); Takashi Yoshiyama (Division of Respiratory Medicine, Japan Anti-Tuberculosis Association, Tokyo, Japan); Jean Pierre Zellweger (Medical Adviser, Tuberculosis Competence Centre, Berne, Switzerland).

WHO Consultants for Systematic Reviews

Saskia Den Boon (Independent consultant, United Kingdom of Great Britain and Northern Ireland); Esmee Doets (Pallas health research and consultancy BV, Rotterdam, The Netherlands); Enrico Girardi (Istituto Nazionale Malattie Infettive L. Spallanzani, Rome, Italy); Darshini Govindasamy (independent consultant, South Africa); Ross Harris (Public Health England, London, United Kingdom of Great Britain and Northern Ireland); Sandra Kik (Mc Gill University, Montreal, Canada); Katharina Kranzer (Department of Infectious Disease and Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom of Great Britain and Northern Ireland); Anouk Oordt-Speets (Pallas health research and consultancy BV, Rotterdam, The Netherlands); Molebogeng Rangaka (Public Health England, London, United Kingdom of Great Britain and Northern Ireland); Monica Sane Schepisi (Istituto Nazionale Malattie Infettive L. Spallanzani, Rome, Italy); Giovanni Sotgiu (Sassari University, Sassari, Italy); Helen Stagg (Public Health England, London, United Kingdom of Great Britain and Northern Ireland); Femke van Kessel (Pallas health research and consultancy BV, Rotterdam, The Netherlands); Anja van't Hoog (Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands); Marije Vonk Noordegraaf-Schouten (Pallas health research and consultancy BV, Rotterdam, The Netherlands).

Peer reviewers

Amy Bloom (US Agency for International Development (USAID), USA); Graham Bothamley (Tuberculosis Network, European Study Group Clinical trials, United Kingdom of Great Britain and Northern Ireland); Gavin Churchyard (The Aurum Institute, South Africa); Daniela Maria Cirillo (San Raffaele del Monte Tabor Foundation, San Raffaele Scientific Institute, Milan, Italy); Raquel Duarte (General Directorate of Health, Portugal); Michel Gasana (National TB Programme, Rwanda); Stephen Graham (Centre for International Child Health, Australia); Connie Erkens (KNCV Tuberculosis Foundation, The Netherlands); Brian Farrugia (Geriatric Medicine and Chest Clinic, Malta); Barbara Hauer (Robert Koch Institute, Germany); Diane Havlir (University of California, San Francisco, USA); Einar Heldal (The International Union against TB and Lung Diseases, Norway); Rein Houben (Tuberculosis Modelling and Analysis Consortium, United Kingdom of Great Britain and Northern Ireland); Mohamed Akramul Islam (BRAC Health Programme, Bangladesh); Jerker Jonsson (Swedish Institute for Infectious Disease Control, Sweden); Michael Kimerling (Bill & Melinda Gates Foundation, USA); Christopher Lange (Clinical Infectious Diseases, Medical Clinic Research Center, Borstel, Germany); Wang Lixia (National Centre for TB control and Prevention, China); Joan O'Donnell (National Disease Surveillance Unit, Ireland); Anshu Prakash (Ministry of Health and Family Welfare, India); Ejaz Qadeer (National TB Control Programme, Federal Ministry of Health, Pakistan); Lidija Ristic (Committee for TB, Ministry of Health, Serbia); Laura Sanchez-Cambronero (Ministry of Health, Social Services and Equality, Spain); Andreas Sandgren (European Centre for Disease Prevention and Control, Stockholm, Sweden); Martina Sester (Saarland University, Germany); Joseph Kimagut Sitienei (Ministry of Public Health, Kenya); Alena Skrahina (Republic Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus); Soumya Swaminathan (National Institute for Research in Tuberculosis, Chennai, India); Ivan Solovic (National Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Slovakia); Elena Sucilene (Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Lithuania); Maarten van Cleeff (Project Director TBCTA, KNCV Tuberculosis Foundation, The Netherlands); Francis Varaine (International Medical Co-ordinator, Médecins sans Frontières, France); Martina Vasakova (Respiratory Diseases and

Pulmonology Department at Thomayer Hospital Prague, Czech Republic); Irina Vasilyeva (Ministry of Health, Russian Federation); Mercedes Vinuesa Sebastián (Ministry of Health, Spain); Brita Askeland Winje (Norwegian Institute of Public Health, Norway); Dalene von Delft (TB PROOF, Cape Town, South Africa); Dominik Zenner (Public Health England, United Kingdom of Great Britain and Northern Ireland).

WHO Headquarters and Regional offices

Mohamed Abdel Aziz (WHO/ EMRO); Masoud Dara (WHO/EURO); Malgorzata Grzemska (WHO/HQ); Ernesto Jaramillo (WHO/HQ); Nobuyuki Nishikiori (WHO/WPRO); Diana Weil (WHO/HQ); Karin Weyer (WHO/HQ).

Acknowledgement of financial support

The development of these guidelines was financially supported by the Ministry of Health of Italy. Core WHO funds were used as well. The European Centre for Disease Prevention and Control supported the systematic review entitled “What interventions are effective to improve initiation, adherence and completion of LTBI treatment?”, through a contract to Pallas health research and consultancy BV. Similarly Public Health England supported the systematic reviews on “Predictive utility of the tuberculin skin test and interferon-gamma release assay among individuals who are not prescribed tuberculosis preventive therapy” and “Systematic literature review and meta-analysis on the best treatment options for latent tuberculosis infection”.

Abbreviations

GRADE	Grading of Recommendations Assessment, Development and Evaluation
IGRA	interferon-gamma release assays
LTBI	latent TB infection
MDR-TB	multidrug-resistant TB
TNF	tumour necrosis factor
TST	Mantoux tuberculin skin test

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27631

